← brief for 2026-08-10 · Slowing decline

Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease

Key takeaways

In children with chronic kidney disease, dapagliflozin, an SGLT2-inhibitor drug, helped protect kidney function and cut protein loss in the urine. This is an encouraging result in a group where these drugs are still new. The exact number of children and length of follow-up were not available in this record.

Who did this work

Farahnak Assadi (Rush University Medical Center) · Elham Bidabadi (Guilan University of Medical Sciences) · Mojgan Mazaheri (Milad Hospital) · Fatemeh Ghane-Sharbaf (Mashhad University of Medical Sciences) · Toktam Faghihi (Tehran University of Medical Sciences) · Rama Naghshizadian (Kurdistan University of Medical Sciences) · Alireza Eskandarifar (Kurdistan University of Medical Sciences) · Anoush Azarfar (Mashhad University of Medical Sciences) · Simin Sadeghi-Bojd (Zahedan University of Medical Sciences) · Arash Abbasi (Children's Medical Center) · Behnaz Bazargani (Children's Medical Center) · Afshin Safaei-asl (Guilan University of Medical Sciences)

Source

Indexed paper · OpenAlex — CKD concept sweep (DB seed + weekly delta) · 2026-08-06
https://doi.org/10.1093/ndt/gfag177